Novartis | NVS - Beneficio Bruto En Ventas

Precio De Mercado
147.55
Cambio Diario
-2.19 -1.46%
Mensual
-9.29%
Anual
30.18%
Q1 Expectativa
149.59




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bausch Health Companies USD 1.93B 165M 2025-09
Biogen USD 1.65B 34.6M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Canopy Growth CAD 21.9M 3.86M 2025-09
Corcept Therapeutics USD 199.58M 3.46M 2025-12
Drreddys Laboratories INR 46.81B 10.24B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
J&J USD 16.6B 118M 2025-12
Merck USD 13.42B 431M 2025-09
Novartis USD 10.82B 695M 2025-09
Novartis USD 10.82B 694M 2025-09
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 157.37M 5.79M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Sanofi EUR 8.45B 3.02B 2025-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Zoetis USD 1.64B 73M 2025-12